SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances announcement that it will present positive Phase 2 lifileucel results in previously treated metastatic NSCLC, alongside a precision-medicine update, has sparked attention around the therapys potential beyond melanoma. Traders are largely bullish, while some caution that detailed efficacy results have not been disclosed and buyout or short-squeeze claims remain speculation.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabets quarterly earnings miss and heavy AI infrastructure spending, which weighed on cash flow, drove the selloff; traders also debated softer search and advertising trends against strong Google Cloud growth. The reaction is split between concerns that spending may not deliver returns soon and dip-buying optimism about Alphabets AI and cloud prospects.

Alphabet Inc - Ordinary Shares - Class C

Alphabets earnings miss and heavy AI infrastructure spending, which pressured cash flow, are driving the selloff. Traders are split between concerns about spending, search growth and AI returns, and dip-buying arguments that strong cloud growth and long-term AI potential outweigh the setback.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNows mixed quarterly reportan earnings miss and softer forward contract-growth guidance despite revenue growth and a higher AI targetsparked a sharp selloff. Traders debate whether the outlook signals slowing growth and AI-driven pressure on software, or whether the market overreacted to a strong underlying business.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Reports that Marvell is in advanced talks to acquire Lumentum have fueled attention, with traders debating the strategic fit in AI data-center optics. The talks remain unconfirmed and no final deal has been reached; some traders are optimistic about a takeover, while others question the financing and warn the rumor-driven move may fade.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsofts quarterly results beat expectations, with accelerating Azure growth and stronger-than-expected guidance helping ease concerns about AI infrastructure spending. Traders reacted positively, though some questioned the scale and returns of continued capex as the after-hours gains faded amid broader tech volatility.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Trian and its partners non-binding proposal to take Wendys private is driving attention, with the board reviewing the offer and no guarantee a deal will proceed. Many traders view it as a lowball bid and argue for a higher offer, while others doubt a deal or bidding war will materialize; short-squeeze speculation is also prominent.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

VKTX is drawing attention after its quarterly update and conference call, with traders focused on the longer-than-expected path to VK2735 commercialization and the lack of a partnership or buyout announcement. The debate centers on whether the company should commercialize independentlyraising concerns about cash burn and dilutionor partner or sell, while bulls point to advancing Phase 3 trials and a substantial cash runway.

Fortinet, Inc. provides cybersecurity solutions to a variety of businesses, such as enterprises, communication service providers, government organizations, and small to medium-sized businesses. Its product portfolio includes network security, secure access service edge, enterprise networking, security operations, application security, and operational technology. The company was founded by Ken Xie and Michael Xie in November 2000 and is headquartered in Sunnyvale, CA.

Fortinet Inc

Fortinets quarterly report triggered a sharp selloff despite beating headline estimates and raising its overall outlook; traders focused on weaker gross margins, decelerating billings and product growth, and a reduced services forecast. The debate is whether the reaction is an overcorrection to a strong quarter or a justified reset for a richly valued stock facing slower growth.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracles investor-day outlookprojecting strong long-term growth, a path to positive free cash flow, and a cap on additional financinghelped ease concerns about the debt and spending behind its AI data-center buildout and drove a sharp rally. Traders largely welcomed the guidance, while skeptics questioned whether Oracle can execute and sustain the gains.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Notable Wednesday Option Activity: ZVRA, KOD, PEN

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Zevra Therapeutics, Inc (Symbol: ZVRA), where a total volume of 8,827 contracts has been traded thus far today, a contract volume which is representative of appr...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA PR Newswire NEW YORK, Aug. 6, 2026 NEW YORK, Aug. 6, 2026 /PRNewswire...

Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates

Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of +212.50% and +22.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Zevra Therapeutics (ZVRA) Securities Investigation Notice - Levi & Korsinsky

Zevra Therapeutics (ZVRA) Securities Investigation Notice - Levi & Korsinsky Zevra Therapeutics (ZVRA) Securities Investigation Notice - Levi & Korsinsky PR Newswire NEW YORK, Aug. 3, 2026 Zevra investors who relied on public statements about arimoclomol's approval status faced losses after the...

Ono Pharmaceutical Co. (OPHLF) Q1 Earnings and Revenues Top Estimates

Ono Pharmaceutical Co. (OPHLF) delivered earnings and revenue surprises of +60.00% and +5.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA PR Newswire NEW YORK, July 30, 2026 NEW YORK, July 30, 2026 /PRNewswire...

ZVRA Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Zevra Therapeutics (ZVRA)

On July 24, 2026, Zevra Therapeutics (NASDAQ: ZVRA) shares fell approximately 24% after the European Medicines Agency's Committee for Medicinal Products for Human Use issued a negative opinion on the Marketing Authorization Application for arimoclomol, branded Meplyffa, for Niemann-Pick disease...

ZVRA SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Zevra Therapeutics

ZVRA SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Zevra Therapeutics ZVRA SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Zevra Therapeutics PR Newswire NEW YORK, July 28, 2026 Zevra shareholders...

ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zevra Therapeutics, Inc. (Zevra or the Company) (NASDAQ: ZVRA) for violations of the securities laws.INVESTIGATION DETAILS: The investigation...

Zevra Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Zevra Therapeutics (ZVRA)

Zevra Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Zevra Therapeutics (ZVRA) Zevra Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Zevra Therapeutics (ZVRA) PR Newswire NEW YORK, July 27...

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

ZVRA Stock Sinks 23% On EU Setback — Analyst Says Risk Is ‘A Headwind, But Not Insurmountable’

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>Zevra plans to request a re-examination and will submit a detailed response.</li><li>H.C. Wainwright called the negative opinion on Zevra Therapeutics’ marketing application for arimoclomol “a disappointing outcome that clearly increases the regulatory risk around the European opportunity.”</li><li>Arimoclomol is already approved and marketed in the U.S. under the brand name MIPLYFFA.</li></ul>Shares of Zevra Therapeutics (ZVRA) fell by as much as 27% on Friday but pared some losses after H.C. Wainwright noted that the company’s recent setback for its drug arimoclomol in Europe was “not insurmountable.”At the time of writing, the stock was down 23%, on track for its worst day since March 2021.<h2 class="st-heading-2">ZVRA’s Setback</h2>On Friday, Zevra announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion on its application to market arimoclomol for Niemann-Pick disease type C (NPC), a rare progressive neurodegenerative disorder. &nbsp;The committee concluded that the drug’s effectiveness had not been clearly proven. It cited uncertainties in how the trial data were handled and analyzed, and noted no clear benefit in walking ability or cognition. Although patients already taking miglustat, alongside arimoclomol, showed some positive signs, these were not considered robust enough for the overall population. As a result, the benefits did not outweigh the risks, the committee said. &nbsp;Zevra plans to request a re-examination and will submit a detailed response. CEO Neil F. McFarlane said the company remains “confident in the totality of evidence” and is committed to finding pathways to bring the treatment to European patients.<h2 class="st-heading-2">Analyst Weighs In</h2>H.C. Wainwright called the negative opinion on Zevra Therapeutics’ marketing application for arimoclomol “a disappointing outcome that clearly increases the regulatory risk around the European opportunity.” The firm maintained its ‘Buy’ rating and $26 price target, noting that Zevra plans to request a re-examination and that this is not the end of the process. Analysts left estimates and valuation unchanged ahead of the company’s August 5 earnings call.Arimoclomol is already approved and marketed in the U.S. under the brand name MIPLYFFA. The FDA cleared it in September 2024 as the first treatment for neurological symptoms of NPC in patients aged 2 years and older, used in combination with miglustat. MIPLYFFA generated $87.4 million in net revenue for the full year 2025 and accounted for a lion’s share of the company's total net revenue of $106.5 million.<h2 class="st-heading-2">How Did ZVRA Retail Traders React?</h2>On Stocktwits, retail sentiment around ZVRA stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user noted that Zevra has not provided details pertaining to the timeline for its further submission.<stembedurl>https://www.stocktwits.com/Smedley1/message/659962885</stembedurl>Another opined that Zevra’s success may come down to whether its drug is superior to privately held pharma company IntraBio’s Aquneursa, also approved for Niemann-Pick disease Type C.<stembedurl>https://www.stocktwits.com/Wahoos/message/659959655</stembedurl><a href="https://stocktwits.com/symbol/ZVRA">ZVRA stock</a> has gained 8% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/mnkd-stock-rises-8-on-furoscix-ready-flow-approval-and-50-m-funding-boost/cZZpTilR7zc">MNKD Stock Rises 8% On Furoscix ReadyFlow Approval And $50M Funding Boost</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In the wake of OWL's redemption restrictions, Senator Elizabeth Warren called for tighter oversight of private credit.

Zevra plans to request a re-examination and will submit a detailed response.H.C. Wainwright called the negative opinion on Zevra Therapeutics’ marketing application for arimoclomol “a disappointing outcome that clearly increases the regulatory risk around

On Friday, Zevra announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion on its application to market arimoclomol for Niemann-Pick disease type C. 

iShares Russell 2000 ETF

Vanguard Total Stock Market ETF

Yes, the bottom is in

No, more downside ahead

Too early to tell

Depends on the stock

Neocloud stocks like $NBIS, $CRWV, $IREN, and $APLD are rebounding after a brutal October. Have they bottomed?

Current Price	$10.31
Prev Close	$10.06
Open	$10.00
Dividend Yield	0.00%
50-Day Moving Average	$11.24
Beta	0.79
Avg. Volume	965,603.56
PE Ratio	11.12

52-Week High	$15.04
52-Week Low	$8.01
Market Capitalization	$597.1M
EPS (Annual)	$1.35
Price to Book	2.81
Revenue Per Employee	$1.75M

Feed

News

Sentiment

Earnings

Fundamentals

Info

ZVRA Fundamentals